These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 15361855)

  • 21. An immunohistochemical panel to distinguish ovarian from uterine serous papillary carcinomas.
    Zhang Y; Garcia-Buitrago MT; Koru-Sengul T; Schuman S; Ganjei-Azar P
    Int J Gynecol Pathol; 2013 Sep; 32(5):476-81. PubMed ID: 23896709
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum.
    Attanoos RL; Webb R; Dojcinov SD; Gibbs AR
    Histopathology; 2002 Mar; 40(3):237-44. PubMed ID: 11895489
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers.
    Wei SH; Chen CM; Strathdee G; Harnsomburana J; Shyu CR; Rahmatpanah F; Shi H; Ng SW; Yan PS; Nephew KP; Brown R; Huang TH
    Clin Cancer Res; 2002 Jul; 8(7):2246-52. PubMed ID: 12114427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Expression and significance of microRNAs in the p53 pathway in ovarian cancer cells and serous ovarian cancer tissues].
    Zhang Q; He XJ; Ma LP; Li N; Yang J; Cheng YX; Cui H
    Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):885-90. PubMed ID: 22340095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ROR2 induces cell apoptosis via activating IRE1α/JNK/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo.
    Li R; Liu T; Shi J; Luan W; Wei X; Yu J; Mao H; Liu P
    J Transl Med; 2019 Dec; 17(1):428. PubMed ID: 31878941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Expression and promotor methylation of p73 gene in ovarian epithelial tumors].
    Zhang YL; Guo XR; Shen DH; Cheng YX; Liang XD; Chen YX; Wang Y
    Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):33-8. PubMed ID: 22455848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PAX 2: a novel Müllerian marker for serous papillary carcinomas to differentiate from micropapillary breast carcinoma.
    Chivukula M; Dabbs DJ; O'Connor S; Bhargava R
    Int J Gynecol Pathol; 2009 Nov; 28(6):570-8. PubMed ID: 19851209
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histologic type, organ of origin, and Wnt pathway status: effect on gene expression in ovarian and uterine carcinomas.
    Shedden KA; Kshirsagar MP; Schwartz DR; Wu R; Yu H; Misek DE; Hanash S; Katabuchi H; Ellenson LH; Fearon ER; Cho KR
    Clin Cancer Res; 2005 Mar; 11(6):2123-31. PubMed ID: 15788657
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Upregulation of phosphorylated cofilin 1 correlates with taxol resistance in human ovarian cancer in vitro and in vivo.
    Li M; Yin J; Mao N; Pan L
    Oncol Rep; 2013 Jan; 29(1):58-66. PubMed ID: 23064469
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gene expression profiles in three histologic types, clear-cell, endometrioid and serous ovarian carcinomas.
    Pamuła-Piłat J; Rubel T; Rzepecka IK; Olbryt M; Herok R; Dansonka-Mieszkowska A; Grzybowska E; Kupryjańczyk J
    J Biol Regul Homeost Agents; 2014; 28(4):659-74. PubMed ID: 25620176
    [TBL] [Abstract][Full Text] [Related]  

  • 31. E2Fs mediate a fundamental cell-cycle deregulation in high-grade serous ovarian carcinomas.
    De Meyer T; Bijsmans IT; Van de Vijver KK; Bekaert S; Oosting J; Van Criekinge W; van Engeland M; Sieben NL
    J Pathol; 2009 Jan; 217(1):14-20. PubMed ID: 18991331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High expression of tissue inhibitor of metalloproteinase-2 in serous ovarian carcinomas and the role of this expression in ovarian tumorigenesis.
    Kim TJ; Rho SB; Choi YL; Choi CH; Lee JW; Bae DS; Ahn G; Lee JH; Kim BG
    Hum Pathol; 2006 Jul; 37(7):906-13. PubMed ID: 16784992
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Microparticles from ovarian carcinomas are shed into ascites and promote cell migration.
    Press JZ; Reyes M; Pitteri SJ; Pennil C; Garcia R; Goff BA; Hanash SM; Swisher EM
    Int J Gynecol Cancer; 2012 May; 22(4):546-52. PubMed ID: 22315094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of microRNA expression in serous ovarian carcinoma.
    Li Y; Yao L; Liu F; Hong J; Chen L; Zhang B; Zhang W
    Int J Mol Med; 2014 Aug; 34(2):491-8. PubMed ID: 24939816
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Microarray expression identification of differentially expressed genes in serous epithelial ovarian cancer compared with bulk normal ovarian tissue and ovarian surface scrapings.
    Grisaru D; Hauspy J; Prasad M; Albert M; Murphy KJ; Covens A; Macgregor PF; Rosen B
    Oncol Rep; 2007 Dec; 18(6):1347-56. PubMed ID: 17982616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma.
    Trinh XB; Tjalma WA; Dirix LY; Vermeulen PB; Peeters DJ; Bachvarov D; Plante M; Berns EM; Helleman J; Van Laere SJ; van Dam PA
    PLoS One; 2011; 6(7):e22469. PubMed ID: 21799864
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling.
    Santin AD; Zhan F; Bellone S; Palmieri M; Cane S; Gokden M; Roman JJ; O'Brien TJ; Tian E; Cannon MJ; Shaughnessy J; Pecorelli S
    Br J Cancer; 2004 May; 90(9):1814-24. PubMed ID: 15208622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of nuclear factor-kappa B enhances the tumor growth of ovarian cancer cell line derived from a low-grade papillary serous carcinoma in p53-independent pathway.
    Xiao X; Yang G; Bai P; Gui S; Nyuyen TM; Mercado-Uribe I; Yang M; Zou J; Li Q; Xiao J; Chang B; Liu G; Wang H; Liu J
    BMC Cancer; 2016 Aug; 16():582. PubMed ID: 27484466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased Notch1 expression is associated with poor overall survival in patients with ovarian cancer.
    Alniaimi AN; Demorest-Hayes K; Alexander VM; Seo S; Yang D; Rose S
    Int J Gynecol Cancer; 2015 Feb; 25(2):208-13. PubMed ID: 25611897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.